Scarica l'app Stockscreener
0.943
0.21%
0.002
Pre-mercato:
.92
-0.023
-2.44%
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
APRE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Zentalis Surges 20% on WEE1 Inhibitor Dose Selection—But Is Aprea the Real Winner in This Space? - Barchart.com
Analyst Calls: Is Aprea Therapeutics Inc stock a buy or sell2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Merger Talk: Is Aprea Therapeutics Inc affected by consumer sentimentWeekly Risk Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart.com
Aug Macro: How does Aprea Therapeutics Inc perform in inflationary periodsCPI Data & Precise Buy Zone Tips - baoquankhu1.vn
APRE Breaks Key Resistance—But Bears Still Lurk Below - Bitget
Janus and Tecnoglass Shares Are Soaring, What You Need To Know - Barchart.com
Stryker (SYK): Buy, Sell, or Hold Post Q4 Earnings? - Barchart.com
Simply Good Foods (SMPL) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Squadron reports 1.27M warrant stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Reports Partial Response in APR-1051 Cancer Trial - MyChesCo
Why Apple (AAPL) Shares Are Falling Today - Barchart
Former Aprea CEO Christian Schade joins Frazier after Halda sale - Stock Titan
Here's What to Expect From 3M Company's Next Earnings Report - Barchart
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
Stocks in play: CGI Inc. - Barchart.com
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Aprea closes oversubscribed $30M private placement to fund APR-1051 clinical expansion - TradingView — Track All Markets
Aprea Therapeutics (NASDAQ: APRE) closes $30M oversubscribed funding - Stock Titan
Aug Fed Impact: How does Aprea Therapeutics Inc perform in inflationary periods2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Given Outperform Rating at Wedbush - Defense World
Aprea Therapeutics Announces $30 Million Private Placement - The Globe and Mail
APRE: Wedbush Reiterates 'Outperform' Rating with $7 Target | AP - GuruFocus
Aprea reports confirmed tumor response in WEE1 inhibitor trial - Investing.com
Aprea reports confirmed tumor response in WEE1 inhibitor trial By Investing.com - Investing.com South Africa
Aprea Therapeutics raises $30 million in private placement By Investing.com - Investing.com Australia
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison - Defense World
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching - bitget.com
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc - MarketScreener
Aprea Therapeutics (Nasdaq: APRE) secures $30M and reports WEE1 trial response - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors - marketscreener.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - bitget.com
Aprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement - RTTNews
Aprea Therapeutics raises $30 million in private placement - Investing.com
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):